Paper34827367
Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa.
Farhan SM and 6 others. Antibiotics (Basel), 2021. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa. Papers, record 34827367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34827367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31921603 | In vitro antibacterial activity of curcumin-meropenem combination against extensively drug-resistant (XDR) bacteria isolated from burn wound infections. | Avicenna J Phytomed | 2020 | https://conductscience.org/library/papers/31921603 | PubMed |
| 2 | 10747827 | Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. | J Antimicrob Chemother | 2000 | https://conductscience.org/library/papers/10747827 | PubMed |
| 3 | 17300908 | The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. | Diagn Microbiol Infect Dis | 2007 | https://conductscience.org/library/papers/17300908 | PubMed |
| 4 | 28306360 | The antibiotic pipeline: reviving research and development and speeding drugs to market. | Expert Rev Anti Infect Ther | 2017 | https://conductscience.org/library/papers/28306360 | PubMed |
| 5 | 30389638 | Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates. | J Glob Antimicrob Resist | 2019 | https://conductscience.org/library/papers/30389638 | PubMed |
| 6 | 22779068 | Characterization of carbapenemase genes in Enterobacteriaceae species exhibiting decreased susceptibility to carbapenems in a university hospital in Chongqing, China. | Ann Lab Med | 2012 | https://conductscience.org/library/papers/22779068 | PubMed |
| 7 | 21514795 | In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology. | Int J Antimicrob Agents | 2011 | https://conductscience.org/library/papers/21514795 | PubMed |
| 8 | 30959050 | β-Lactamases and β-Lactamase Inhibitors in the 21st Century. | J Mol Biol | 2019 | https://conductscience.org/library/papers/30959050 | PubMed |
| 9 | 3312985 | Mechanism of bactericidal action of aminoglycosides. | Microbiol Rev | 1987 | https://conductscience.org/library/papers/3312985 | PubMed |
| 10 | 27133391 | Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin. | J Microbiol Immunol Infect | 2019 | https://conductscience.org/library/papers/27133391 | PubMed |
| 11 | 21173183 | Efflux-mediated antibiotic resistance in Acinetobacter spp. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21173183 | PubMed |
| 12 | 11810504 | Activities of beta-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections. | J Infect Chemother | 1999 | https://conductscience.org/library/papers/11810504 | PubMed |
| 13 | 1816177 | Mechanisms of resistance to beta-lactam antibiotics in Acinetobacter calcoaceticus. | J Antimicrob Chemother | 1991 | https://conductscience.org/library/papers/1816177 | PubMed |
| 14 | 19223616 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19223616 | PubMed |
| 15 | 19822890 | Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. | Clin Microbiol Rev | 2009 | https://conductscience.org/library/papers/19822890 | PubMed |
| 16 | 31924522 | In vitro effect of an antimicrobial combination therapy without colistin and tigecycline for CPE and non-CPE. | J Infect Chemother | 2020 | https://conductscience.org/library/papers/31924522 | PubMed |
| 17 | 15131172 | PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. | J Clin Microbiol | 2004 | https://conductscience.org/library/papers/15131172 | PubMed |
| 18 | 16504059 | Statistical analysis of real-time PCR data. | BMC Bioinformatics | 2006 | https://conductscience.org/library/papers/16504059 | PubMed |
| 19 | 29420743 | Meropenem potentiation of aminoglycoside activity against Pseudomonas aeruginosa: involvement of the MexXY-OprM multidrug efflux system. | J Antimicrob Chemother | 2018 | https://conductscience.org/library/papers/29420743 | PubMed |
| 20 | 31406468 | Antimicrobial resistance pattern and molecular genetic distribution of metallo-β-lactamases producing Pseudomonas aeruginosa isolated from hospitals in Minia, Egypt. | Infect Drug Resist | 2019 | https://conductscience.org/library/papers/31406468 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42837086 | Surface charge-dependent effects of BSA-curcumin nanoparticles combined with amikacin in antimicrobial photodynamic therapy: A pilot In Vivo study of multidrug-resistant Pseudomonas aeruginosa skin infection. | Lasers Med Sci | 2026 | https://conductscience.org/library/papers/42837086 | PubMed |
| 42197354 | Synergistic Inhibition of Acinetobacter baumannii Biofilm Formation and Reduction of Lung Inflammation In Vivo by Combination of α-Pinene and Meropenem. | Microorganisms | 2026 | https://conductscience.org/library/papers/42197354 | PubMed |
| 42194908 | Study of the Impact of Antibiotic Combinations Used in Urinary Tract Infections on the Effectiveness of Antimicrobial Therapy. | J Clin Med | 2026 | https://conductscience.org/library/papers/42194908 | PubMed |
| 41925990 | In Vitro Antibacterial Effect of Probiotics Against Bacterial Isolates from Diabetic Foot Ulcers in Ain Shams University Hospitals. | Probiotics Antimicrob Proteins | 2026 | https://conductscience.org/library/papers/41925990 | PubMed |
| 41720900 | Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates. | Sci Rep | 2026 | https://conductscience.org/library/papers/41720900 | PubMed |
| 41463779 | Occurrence of Virulence and Antibiotic Resistance in Pseudomonas aeruginosa Isolated from the Environmental Water from Tamaulipas, Mexico. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41463779 | PubMed |
| 40572777 | A Retrospective Study on the Prevalence and Antimicrobial Susceptibility of Gram-Positive Cocci in a Pediatric Department: A Single-Center Report from Egypt. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40572777 | PubMed |
| 40428842 | The Efficacy and Tolerability of Colistin Versus Non-Colistin Antimicrobial Regimens Among Hospitalized COVID-19 Patients with Multidrug-Resistant Bacterial Superinfection: An Observational Multicenter Study. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40428842 | PubMed |
| 40131859 | RETRACTED: The effect of biosynthesized silver nanoparticles on Pseudomonas aeruginosa-infected dogs wounds. | PLoS One | 2025 | https://conductscience.org/library/papers/40131859 | PubMed |
| 39354545 | Investigation of in vitro susceptibility and resistance mechanisms to amikacin among diverse carbapenemase-producing Enterobacteriaceae. | BMC Med Genomics | 2024 | https://conductscience.org/library/papers/39354545 | PubMed |
| 38116135 | Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Pseudomonas aeruginosa. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/38116135 | PubMed |
| 37895978 | Comparative Investigation into the Roles of Imipenem:Cyclodextrin Complexation and Antibiotic Combination in Combatting Antimicrobial Resistance in Gram-Negative Bacteria. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37895978 | PubMed |
| 36830309 | Evidence-Based Treatment of Pseudomonas aeruginosa Infections: A Critical Reappraisal. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36830309 | PubMed |
| 36318447 | The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection. | Vet Med Sci | 2023 | https://conductscience.org/library/papers/36318447 | PubMed |
| 36281514 | Emergence of NDM-1-producing Pseudomonas aeruginosa Sequence Type 773 Clone: Shift of Carbapenemase Molecular Epidemiology and Spread of 16S rRNA Methylase Genes in Korea. | Ann Lab Med | 2023 | https://conductscience.org/library/papers/36281514 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34827367
GET https://conductscience.org/api/papers/v1/34827367/references?page=2